Adagio Medical reveals initial acute findings from the FULCRUM-VT study
Study Overview: Adagio Medical presented preliminary results from the FULCRUM-VT Study, which evaluated Ultralow Temperature Cryoablation for treating Sustained Monomorphic Ventricular Tachycardia in patients with ischemic and non-ischemic cardiomyopathy at a symposium in Philadelphia.
Results and Efficacy: The study involved 207 patients, achieving an acute clinical success rate of 97.4% in eliminating target ventricular arrhythmias, with a mean procedure duration of 206 minutes.
Safety Findings: The study reported a 2.5% rate of major adverse events, including four peri-procedural deaths, one of which was determined to be definitely related to the investigational device.
Presentation Details: The findings were presented by Dr. Travis Richardson from Vanderbilt University Medical Center during a Late Breaking Clinical Trials Session at the 20th Annual International Symposium on Ventricular Arrhythmias.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on ADGM
About ADGM
About the author
Insider Buying Update for Wednesday, December 17: SRRK, ADGM
Insider Purchase at Scholar Rock: Srinivas Akkaraju bought 29,599 shares of Scholar Rock Holding (SRRK) for $1.18M at $39.92 each, seeing a 13.5% gain during the trading session.
Previous Investment by Akkaraju: Prior to this purchase, Akkaraju had acquired $18.81M worth of shares at $37.58 each within the last year.
Adagio Medical Holdings CEO Purchase: Todd Usen, CEO of Adagio Medical Holdings, purchased 207,315 shares for $225,973 at $1.09 each, while the stock was down about 2.5% on the day.
Market Performance: Scholar Rock Holding's stock was up approximately 0.4% on Wednesday, with SRRK reaching a high of $45.32 during trading.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
